Transonic[®] HD03 **Hemodialysis Monitoring**

Delivered Flow Recirculation Access Flow



HD03 Monitor displays vascular access flow results

Measure Dialysis Adequacy Delivered Flow and Recirculation results identify dose delivery problems in the AV Access and Central Venous Catheters allowing the nurse to optimize the treatment on-the spot!

Trend Vascular Access Flow

A drop in Access Flow signals the onset of a stenosis, in time for proactive minimally invasive intervention. A high Access Flow can signal a potential high-output cardiac failure.



HD03Monitoring(DL-101-ds)RevC2022USltr

HD03 Features & Benefits

HD03 Measurements

HD03 measurements can be performed on all Chronic or Acute Adult, and Pediatric Hemodialysis patients' AV fistulas, grafts and catheters during routine dialysis.

Easy to Use

The HD03 is operator independent and very easy to use with on-screen step-by-step procedure.

Quick and Accurate

Results are displayed immediately on the HD03 monitor screen.

Choice of Results

You have a choice of:

1) HD03 Patient-less Measurement Module (PMM) that displays measurement results to be manually recorded in a patient's chart.

Or

2) HD03 Administrator Management Software (DTM) that trends and archives measurement results under a patient's name. **Note:** This device is not available in countries requiring European Medical Device Regulation (MDR) clearance.

HD03 Monitor

Portable

Rechargeable battery permits portable, easy mobility between patients.

Safety/Infection Control

Touch-screen input prevents cross contamination. The screen can be cleaned with a diluted solution of bleach or soap.

H4FX Flow/Dilution Sensors

Paired sensors pass ultrasound waves through dialysis tubing to measure blood flow and other parameters.

- Sensors clip onto tubing connected to the patient's blood lines.
- Saline can be released directly from saline bag or infused into the dialysis circuit.





HD03 Monitoring of Dialysis Adequacy in Arteriovenous Grafts and Fistulas

- Measure True Delivered Blood Flow to Optimize Dialysis Delivery
- Measure Recirculation to Identify Formation of Stenoses



Measure Access Recirculation

With a single infusion of saline, the Transonic Hemodialysis® Monitor detects and quantifies access recirculation, a late indicator of a failing access. Because Transonic® ultrasound dilution technology can separate cardiovascular recirculation from cardiopulmonary recirculation, 0% recirculation can be quantified. Measurement of recirculation will:

- Identify inadvertent reversal of blood lines (see box at right);
- Confirm proper needle placement;
- Confirm 0% recirculation, or identify recirculation percentage, if present.



Indicator concentration curves showing 18% access recirculation. Dialysis Adequacy(DL-120-fly)RevC2022US

Measure Delivered Blood Flow

Pump flow errors and recirculation compromise dialysis delivery of a KT/V prescription. The Transonic[®] Hemodialysis Monitor measures true delivered blood flow through dialysis tubing using transittime ultrasound technology. By comparing true delivered blood flow to the pump's reading, any flow limiting cause such as small needle diameter or incorrect needle placement can be identified and corrected. Delivered Blood Flow is used to:

- Determine the most appropriate blood pump setting for a low flow access when it is not feasible to increase access flow;
- Find the cause of excessive negative arterial pressure;
- Test blood pump calibration and its "effective flow" algorithm;
- Diagnose tubing set flow restrictions that could cause hemolysis.

Case Report:

Inadvertent Reversal of Blood Lines

When a routine Transonic[®] hemodialysis screening of a 41-year-old female ESKD patient with an AV graft reported a vascular access recirculation of 22%, the nurse reversed the blood lines and performed a second recirculation measurement. Zero percent recirculation registered. This demonstrated that the hemodialysis lines had been inadvertently reversed when they were first connected for hemodialysis. By leaving the lines in the correct position for the duration of the dialysis session, the patient received her prescribed dialysis prescription.



HD03 Monitoring of Dialysis Adequacy in Central Venous Catheters (CVCs)

Measure True Delivered Blood Flow and Recirculation in CVCs On-the-Spot to Optimize Dialysis Delivery



Catheter Adequacy

Most End-Stage Kidney Disease (ESKD) patients will undergo, at some point, dialysis administered through a Central Venous Catheter. Whether dialysis is emergent and temporary, acute or chronic, CVCs will often underdeliver dialysis due to:

- a discrepancy between a dialyzer's pump setting and its true delivered flow;
- and/or the presence of recirculation during dialysis delivery.

Example: Flow-QC Adequacy Test Detects Hemolysis Risk

75-year-old woman with Central Venous Catheter: Blood Lines: normal line position; Pump Setting: 300 mL/min; Delivered Blood Flow: 190 mL/min; Recirculation: 0%.

A 35% disparity between 300 mL/min pump setting and 190 mL/min delivered blood flow indicated significant hemolysis risk.

Response: Lines were checked to see that they were not kinked. Blood lines were then reversed; the pump was reset to 300 mL/min. Delivered blood flow & recirculation were again measured.

- Delivered Flow: 290 mL/min
- Flow-QC Recirculation: 2-3%

Results: The patient received better treatment with the lines in a reversed position and the pump delivering 290 mL/min.

Take Home: Treatment of patients with CVCs can be optimized with Flow-QC Delivered Flow and Recirculation measurements.

Transonic HD03 Flow-QC[®] Monitoring of Catheter Dose Delivery

Two potential pitfalls plague the use of catheters for dialysis delivery.

- 1. A fibrin sheath can occlude the lumen of the catheter's arterial entry port, impeding flow and causing a severe drop in dialysis dose delivery. This can be identified on the spot and often corrected with an HD03 measurement of true delivered blood flow.
- 2. The close proximity of the catheter's arterial entry and venous return ports make recirculation possible in some catheter designs. For instance, if there is 10% recirculation, the amount of blood cycled through the dialyzer is effectively 10% less and underdialysis can occur. Since the HD03 Monitor can measure recirculation, recirculation in catheters can be identified and optimized to provide the most efficient dialysis possible.

Transonic's HD03 Hemodialysis Monitor Measurements Optimize Dialysis Catheter Delivery by:

- Helping to establish a maximum dialysis pump setting before recirculation occurs;
- Using known values for flow and recirculation to adjust the length of dialysis;
- Identifying flow restrictions;
- Finding the best catheter configuration between the catheter blood lines (regular or reversed).



HD03 Measurements of Vascular Access Flow in AV Grafts and Fistulas

Transonic[®] Hemodialysis Monitor identifies vascular access dysfunction and risk of thrombosis

Vascular Access Flow

Access flow is the quintessential vital sign for an AV Access. Insufficient flow causes underdialysis. Still lower flow invites thrombosis. Too much flow can lead to heart problems. Each condition harbors associated morbidities.

Transonic[®] ultrasound dilution technology is an intra-access flow measurement technology to detect flow limiting problems wherever they occur within a vascular access during the dialysis session. The method uses Transonic[®] Hemodialysis Monitors and Flow/Dilution Sensors to measure access flow directly for an instant snapshot of access function.

By measuring vascular access flow routinely and trending the results over several months, a record of access patency is created. A drop in access flow signals formation of a stenosis, in time for proactive minimally invasive intervention.

Access Flow enables clinicians to detect onset of stenosis before thrombosis occurs.





Access flow measurement with the Transonic® Hemodialysis Monitor.



Fistula and Graft Access Flow Interpretation

Lower A	Arm AV	/F (wrist	and abov	e)							
200 4	100	600	800	1000	1200	140	0 16	i00	1800	2000	2200
Upper A	Arm AV	/F (elbow	and abo	ve)							
200 40	0 600	800	1000	1200	1400	1600	1800	2000	2200) 2400	2600
AV Grat	ft (forear	rm loop gr	aft)								
200 4	100 6	500	800	1000	12	00	1400	160	0 1	1800	2000
Consid Exami	ler Clinica nation &	al Ima <mark>ging</mark>	AC If Co	Flow Is Stonic Flow Is Stonitoring. Insider Cl	eady, Co If 25% inical Ex	ontinue Decreas am & Ir	se Occur naging	AC Ev s, sig hi	aluate gns and gh outp	the pation sympto out cardia	ent for ms of ac failu
Actual flo Actual flo A clinical as part of Transonic examinat Snuffbox the anast Upper an A potenti	ow levels examina f the pre- c access fl ion to de or endov comosis a m AV fist ial for car	for AV fis tion (look cannulati ow measu etect/conf vascular fi nd the ve ulas typic rdiac over	tula and , listen, f on proce urements irm indic stulas ma ssel's out ally have load exis ardiac fa	graft pat eel, arm are inter ations of ay have a flow con a higher ts at flow	ients sh elevatio access c lower a figuratio access f >1600-	ould be n and a be utili lysfunct ccess flo on. low rar 3000 m	e custom nugment zed in co tion. ow rang nge due L/min. E	ized by ation) s onjunct e depe to the l valuate	the ne should ion wit nding c arger a patien	ephrolog be used h a clinic on the lo ortery siz at for sig	ist. routine cal cation e. ns and
symptom	s of high	-output c		nur e.							
symptom	S of high	rs.	Transonie equipme flowmete intervent pressure	c Systems Ir nt. Founded ers and mor tional radio and pressu	nc. is a glo l in 1983, nitors for logy and re volume	obal man Transoni surgical, research a systems	ufacturer c sells "go hemodialy application , laser Dop	of innova Id stand rsis, pedi ns. In ado opler flov	ative bior ard" trar atric criti dition, Tra vmeters	medical me nsit-time u cal care, p ansonic pr and telem	easureme Itrasouno erfusion, ovides etry syste

Transonic Systems Inc. Tel: +1 607-257-5300 Fax: +1 607-257-7256 support@transonic.com Transonic Europe B.V. Tel: +31 43-407-7200 Fax: +31 43-407-7201 europe@transonic.com

Transonic Asia Inc. Tel: +886 3399-5806 Fax: +886 3399-5805 support@transonicasia.com Nipro-Transonic Japan In Tel: +81 04-2946-8541 Fax: +81 04-2946-8542

japan@transonic.com

HD03 Hemodialysis Monitor Specifications

Two HD03 system configurations address different user needs.

- Patient-less Measurement Module (PMM): does not save any patient information or measurement data.
- Data Transfer Module (DTM): records patient information & measurement data to be transferred to a computer loaded with HD03 Administrative software for further analysis.

VASCULAR ACCESS TYPE	TRANSONIC MEASUREMENT	CLINICAL APPLICATION		
Catheter	Delivered Flow; Recirculation	Dialysis optimization with simple algorithm. Outcomes: improved adequacy; decreased use of thrombotic agents; decreased catheter exchange.		
AV Fistula and/or graft	Delivered Flow; Recirculation; Vascular Access Flow	Detection of access dysfunction with customized AVF/AVG protocols. Detection of high flow access and related high flow cardiac failure. Outcomes: improved management of access intervention and measurement to manage intervention outcomes; Cardiac care intervention to reduce morbidity and mortality; Assist with kidney transplant listing.		

HD03 Specifications

PHYSICAL PARAMETERS

Weight: 6 lbs (2.7 Kg) Dimensions: 9.5" x 11.5" x 7" (24cm x 29cm x 18cm) Display: VGA LCD Interactive Touch Screen (8.4") (21cm) USB Port: Type A; For connection to Transonic DTM only Sensor Connector: 36-pin high-density connector

POWER SUPPLY

External AC Input: 100 - 240 VAC (±10%); 50-60 Hz. nominal External Connector: International 3 conductor type IEC 320 Output: 15 VDC, 2.6A

Battery: 12.6 VDC (max) 8.7 Ahr (min) Li-ion

ELECTRICAL ISOLATION

Hemodialysis monitor complies with USA standards for medical and dental equipment (IEC60601), and with European standards for medical and ultrasonic apparatus (DIN IEC 601-1, VDE 0750 -1/5.82, IEC 62D Sec. 31). Input leakage current < 50 uA; Patient leakage current < 10 uA; Patient Isolation > 2500 V, double insulated. Meets IEC 60601-1 Cardiac Floating (CF) specification.

H4FX Flow/Dilution Sensors

Sensor pair transmits ultrasound waves through dialysis tubing to measure blood flow and other parameters

Sensors clip onto tubing connected to a patient's blood lines.

H4FX ULTRASONIC SENSOR SPECIFICATIONS

- Frequency of Operation: 3.6 MHz
- Mode of Operation: Transit-time burst excitation, 1.6% duty factor
- Ultrasound Output Level: Factory-set, no interactive system features. Settings use "ALARA" principles (As Low As Reasonably Achievable) and are more than 30dB below FDA "preamendment levels," recognized as acceptable USA insonification limits.

HD03 ACCURACY	(
---------------	---

MEASUREMENT	DELIVERED FLOW	RECIRCULATION	ACCESS FLOW
Range	-2 to +2 L/min	0 to 100%	0 to 4000 ml/min
Accuracy	\pm 6% of the flow reading \pm the zero offset	$> 2\%$ Recirculation detected \pm 3% of displayed value. For example: a 15% reading is between 12% and 18%	The larger of:±100 ml/min ±15% of reading
Repeatability		Clinical correlation coefficient $= 0.98$	Clinical correlation coefficient = 0.98
Maximum zero flow offset:	± 10 ml/min		



HD03 Theory of Operation

Transit-Time Ultrasound Technology: Delivered Flow

A Transonic[®] Clamp-on Flow/Dilution Flowsensor houses ultrasonic transducers and a tubing channel which holds the dialysis tubing containing the fluid being measured. The transducers in the sensor are positioned on opposite sides of the tubing. An electrical excitation from the flow-

meter causes the transducers to emit ultrasound waves that intersect the tubing in both upstream and downstream directions. The ultrasound waves are received by the opposing transducers where they are converted into electrical signals. As the ultrasound waves travel downstream or with the flow within the tube, its velocity increases. As ul-

trasound waves travel upstream or against the flow, its velocity decreases. From these velocity signals, the Flowmeter derives an accurate measure of the "transit time" it takes for the ultrasound wave to travel from one transducer to the other from which it then derives volume flow.

Ultrasound Indicator Dilution Technology: Recirculation and Access Flow

The Transonic Hemodialysis Monitor with its Flow/Dilution Sensors measure ultrasound velocity. The velocity (1560-1590 m/sec) of ultrasound in blood is determined primarily by its blood protein concentration. A bolus of isotonic saline (ultrasound velocity: 1533 m/sec) introduced into the blood stream dilutes the blood and, thereby, reduces its ultrasound velocity. When a bolus of saline indicator is introduced into the blood line, arterial and venous Flow/ Dilution Sensors record this saline bolus as a conventional indicator dilution curve.

The following measurements can be selected:



Bell-shaped saline indicator dilution curve.

HD03Theory of Operation(DL-22-ds)RevC2022USltr



Schematic representation of a Flow/ Dilution Sensor showing the paths of ultrasound signals across the tubing.



Paired arterial & venous Flow/Dilution Sensors.



A touch screen HD03 Monitor attached to an IV pole with paired arterial and venous Flow/Dilution Sensors clamped onto respective arterial and venous lines of Flow-QC tubing. Sensors can be clipped directly on the arterial and venous lines for most measurements and options. This schematic demonstrates the option for saline release into the arterial line for recirculation and access flow measurements.

RECIRCULATION

The Hemodialysis Monitor identifies the direct reflux of the venous saline indicator bolus into the arterial line. The ratio of indicator concentrations equals access recirculation. The HD03 Monitor's high timing resolution separates cardiopulmonary circulation from systemic circulation and allows identification of zero access recirculation.



Normal sensor and reverse line position for access recirculation measurement.



HD03 Theory of Operation cont.

ACCESS FLOW

Access Flow is measured by The Krivitski Method[®], a pioneering Transonic[®] contribution to vascular access management. After reversing the blood lines at the needle connections, the upstream (venous) access needle introduces an indicator into the access flow stream. The downstream (arterial) access needle samples the blood concentration diluted by the indicator.



Reversed line position for access recirculation measurement. Saline injection is still made into the venous line which is now the upstream line.



www.transonic.com

AMERICAS

Transonic Systems Inc. Tel: +1 607-257-5300 Fax: +1 607-257-7256 support@transonic.com

EUROPE

Transonic Europe B.V. Tel: +31 43-407-7200 Fax: +31 43-407-7201 europe@transonic.com

ASIA/PACIFIC

Transonic Asia Inc. Tel: +886 3399-5806 Fax: +886 3399-5805 support@transonicasia.com

Transonic Systems Inc. is a global manufacturer of innovative biomedical measurement equipment. Founded in 1983, Transonic sells "gold standard" transit-time ultrasound flowmeters and monitors for surgical, hemodialysis, pediatric critical care, perfusion, interventional radiology and research applications. In addition, Transonic provides

pressure and pressure volume systems, laser Doppler flowmeters and telemetry systems.

JAPAN

Nipro-Transonic Japan Inc. Tel: +81 04-2946-8541 Fax: +81 04-2946-8542 japan@transonic.com

Hemodialysis Annotated References

Theory & Validations (UDT, TTFM)

Ultrasound Dilution (UDT)

Krivitski NM, **"Novel Method to Measure Access Flow during Hemodialysis by Ultrasound Velocity Dilution Technique,"** ASAIO 1995; 41(3): M741-M745. Theory and bench validation of access flow measurement by ultrasound velocity dilution. Reversal of dialysis lines creates a zone of mixing in the vascular access, allowing the use of dilution technique for access flow measurement. Data show that access flow can be accurately measured by sound velocity dilution technique.

Depner TA, Krivitski NM, MacGibbon D, **"Hemodialysis Access Recirculation (Rc) Measured by Ultrasound Dilution,"** ASAIO J 1995; 41(3): M749-M753. "The data suggest that the ultrasound dilution method is both sensitive and accurate."

Depner TA, Krivitski NM, **"Clinical Measurement of Blood Flow in Hemodialysis Access Fistulae and Grafts by Ultrasound Dilution,"** ASAIO J 1995; 41(3): M745-M749. "These data show that blood flow in peripheral arteriovenous grafts and fistulas can be measured accurately during hemodialysis using ultrasound velocity dilution."

Bosman PJ, Koomans HA *et al*, **"Access flow measurements in hemodialysis patients: in vivo validation of an ultrasound dilution technique." J Am Soc Nephrol. 1996 Jun;7(6):966-9. "***Measurements* **correlated well with flow rates determined by magnetic resonance angiography and by a technique based on intra-access flow-pressure curves. ...Access flow can be measured easily, noninvasively, and reliably by the ultrasound dilution device... The method requires little investment in time making it superior to other methods."**

Krivitski NM, MacGibbon D, Gleed RD, Dobson A, **"Accuracy of Dilution Techniques for Access Flow Measurement During Hemodialysis,"** AJKD 1998; 31(3): 502-508. "An error in access flow measurement of 20% or more arises from the use of flow reading taken from pump setting rather than a measured flow. The discrepancy between the real flow and pump setting is attributable to needle size, vascular access conditions, or pump calibration."

Krivitski NM, Depner TA, **"Cardiac output and central blood volume during hemodialysis: methodology,"** Adv Ren Replace Ther. 1999;6(3):225-232. "*CO and CBV can be routinely and reliably measured during hemodialysis if precautions are taken to avoid specifically identified sources of error.*"

Kislouchine VV, Dean DA, **"Validation of a Novel Ultrasound Dilution Method to Measure Cardiac Output during Hemodialysis,"** ASAIO J 1996; 42(5): M906-M907. *"Cardiac output measured by ultrasound velocity dilution during hemodialysis is in good agreement with well established, but invasive, transit time and pump standards."*

Nikiforov UV, Kisluchine VV, Chaus NI, **"Validation of a New Method to Measure Cardiac Output during Extracorporeal Detoxifica-tion,"** ASAIO J 1996; 42(5) M903-M905. *"Data suggest agreement be-tween the ultrasound dilution technique and thermodilution. Ultrasound dilution is preferable in patients undergoing extracorporeal detoxification when pulmonary artery catheterization is not required or dangerous."*

Transit-time Ultrasound (TTFM)

Drost CJ, **"Volume Flow Measurement System,"** U.S. Patent # 4,227,407, Cornell Research Foundation, Inc., Ithaca, NY, October 14, 1980. "Patent for transit-time ultrasound flow measurements: outlines a device and method for direct measurement of volume flow of fluids through a tube, using an interferometric transit-time technique based on an electric signal which is proportional to fluid flow and is, to a high degree, independent of flow profile, conduit geometry, and alignment of the conduit within the probe."

Drost CJ, "Homogeneous Full Flow Illumination to Ultrasonic

Systems," Proceedings of the 31st Annual Conference of Engineering in Medicine and Biology, Bethesda MD: Alliance for Engineering in Medicine and Biology 1978; 20: 183. "If the signal acquired in ultrasonic blood flow measuring systems could be made to represent the full flow rather than a (spatially often ill defined) portion of one, it is obviously a step closer to instantaneously measuring the total flow independent of flow profile and vessel geometry."

Drost CJ, **"Vessel Diameter-Independent Volume Flow Measurements Using Ultrasound,"** Proceedings of San Diego Biomed. Symposium, San Diego CA: San Diego Biomed. Soc. 1978; 17: 299-302, 1978. *"Theoretical background for a volume flow measuring technique in which volume flow is measured directly, independent of vessel diameter, vessel shape, flow profile or vessel aluignment within the nonconstrictive probe."*

Hemisch W, **"Blood Flow during Cardiovascular Surgery: Methodological, Technical and Practical Considerations,"** Gefäßchirugie, Springer-Verlag, 1996. "*Comparison of Doppler, electromagnetic and transit-time ultrasound technologies noting that transit time ultrasound is the only method able to measure volume flow inside artificial vascular prostheses.*"



Predictive Power of Arteriovenous Access Flow Measurements

Salman L et al, "A multicenter randomized clinical trial of hemodialysis access blood flow surveillance compared to standard of care - The Hemodialysis Access Surveillance Evaluation (HASE) Study," Kidney International Reports (2020), "The HASE study demonstrated that monthly surveillance using UDT flow measurement has resulted in lower per patient and per visit thrombosis rate as compared to the control group."

Aragoncillo I *et al*, **"Adding access blood flow surveillance reduces thrombosis and improves arteriovenous fistula patency: a randomized controlled trial**," J Vasc Access. 2017; 18(4): 352-358. "QA-based surveillance combining Doppler ultrasound and ultrasound dilution reduces the frequency of thrombosis, is cost effective, and *improves thrombosis-free and secondary patency in autologous AV."*

Ashoor IF, Hughson EA, Somers MJ, **"Arteriovenous access monitoring with ultrasound dilution in a pediatric hemodialysis unit."** Blood Purif. 2015;39(1-3):93-8. "Thrombosis rate dropped from 13.5 per 100 patient-months on HD during the baseline period to 3.5 per 100 patient-months on HD during the surveillance period. Ultrasound Dilution surveillance is very sensitive in detecting hemodynamically significant stenosis and can decrease AV access thrombosis rates."

Park HS, Kang SH, Chung BH *et al*, **"Effect of intradialytic change in blood pressure and ultrafiltration volume on the variation in access flow measured by ultrasound dilution,"** Kidney Res Clin Pract. 2013; 32(1):16-20. "Variation in access flow during HD is relatively small. Decreased blood pressure is a risk factor for variation in access flow measured by ultrasound dilution. In most patients whose blood pressures are stable during HD, the access flow can be measured at any time during the HD treatment."

Chan KE, Hakim RM *et al,* **"Access survival amongst hemodialysis patients referred for preventive angiography and percutaneous transluminal angioplasty,"** Clin J Am Soc Nephrol. 2011 Nov; 6(11):2669-80. "Huge statistical study (41, 132 Medicare patients, 1,342 Fresenius facilities, 48 states) determined, "The benefits of PTA *interventions are most seen in newer accesses or accesses with insufficient* flow."

Maoz D, Reinitz R, Schneiderman J *et al*, **"Hemodialysis graft flow surveillance with prompt corrective interventions improves access long-term patency,"** Clin Nephrol. 2009 Jan;71(1):43-9. "Stringent flow surveillance policy coupled with prompt intervention has proven effective in maintaining AVG long-term patency."

van Loon M, Tordoir JH *et al*, **"Implementation of a vascular access quality programme improves vascular access care."** Nephrol Dial Transplant. 2007 Jun;22(6):1628-32. *"(24 center, 2300 patients) An AV Access Care Quality Improvement Plan is worthwhile to improve dialysis patients' care and access morbidity."*

Tessitore N *et al*, **"Adding access blood flow surveillance to clinical monitoring reduces thrombosis rates and costs, and improves fistula patency in the short term: a controlled cohort study,"** Nephrol Dial Transplant 2008 23:3578-3584. "Adding Qa surveillance to monitoring in mature AVFs is associated with a better detection and elective treatment of stenosis, and lower thrombosis rates and access-related costs."

Wijnen E, van der Sande F *et al*, **"Impact of a quality improvement programme based on vascular access flow monitoring on costs, access occlusion and access failure,"** Nephrol Dial Transplant. 2006 Dec;21(12):3514-9. "A quality improvement programme based on periodical access flow measurement reduced the number of acute vascular *access failures due to thrombotic events and also significantly reduced health care costs in patients with AVG, but not in patients with AVF."* Lopot F *et al*, **"Comparison of different techniques of hemodialysis vascular access flow evaluation,"** J Vasc Access. 2004 Jan-Mar;5(1):25-32. "Ultrasound Dilution measurements were used as the gold standard to compare other surveillance methodologies. "The very high reproducibility seen in UD, both for measurements at the same extracorporeal blood flow (QB) and for measurements at two different QB justifies its current status of a reference method in vascular access flow."

Lok CE, Bhola C, Croxford R, Richardson RM, **"Reducing vascular** access morbidity: a comparative trial of two vascular access monitoring strategies," Nephrol Dial Transplant. 2003 Jun;18(6):1174-80. "A three-year study, 300-400 patients. Low flow rates detected using Transonic monitoring were associated with increased thrombosis, while stenosis detected using Duplex ultrasonography was not a strong predictor of incipient thrombosis."

Goldstein SL, Allsteadt A, **"Ultrasound Dilution Evaluation of Pediatric Hemodialysis Vascular Access,"** Kidney Int 2001; 59: *Study supports the use of monthly measurement to prevent access thrombosis in children receiving HD.*

McCarley PB, Ikizler TA *et al*, **"Vascular Access Blood Flow Monitoring Reduces Access Morbidity and Costs,"** Kidney Int 2001; 60:1164-72. *"Vascular access blood flow monitoring along with preventative interventions should be the standard of care in chronic hemodialysis patients. ... The comprehensive cost is markedly reduced due to the decreased number of hospitalizations, catheters placed, missed treatments, and surgical interventions."*

Sands JJ, Jabyac PA, Miranda CL, Kapsick BJ, **"Intervention based** on monthly monitoring decreases hemodialysis access thrombosis," ASAIO J. 1999 May-Jun;45(3):147-50. "We believe that monthly access flow measurement will ensure the lowest incidence of thrombosis and decrease the cost of access maintenance."

Neyra NR, Ikizler TA, May RE, Himmelfarb J, Schulman G, Shyr Y, Hakim RM, **"Changes in access flow over time predicts vascular access thrombosis,"** Kidney Int 1998; 54: 1714-1719. *"There is a 13.6-fold increase in the relative risk of thrombosis for accesses with more than 35% decrease in vascular access blood flow. Study prospectively determined that measurement of blood flow plays an important role in evaluation and detection of PTFE grafts at higher risk of thrombosis"*

May RE, Himmelfarb J, Yenicesu M *et al*, "**Predictive measures** of vascular access thrombosis: A prospective study," Kidney Int 1997;52:1656-1662. Three-center study of 170 patients over six months. "The blood flow by Dilution (for grafts) was the best predictor of thrombosis within the subsequent three months. Multi-variate analysis showed a significantly increasing risk of thrombosis with decreasing access blood flow."

Sands J, Glidden D, Miranda C, **"Hemodialysis access flow measurement. Comparison of ultrasound dilution and duplex ultrasonography."** ASAIO J. 1996 Sep- Oct;42(5):M899-901. *"Measurement of hemodialysis access flow by ultrasound dilution was essentially equivalent to that obtained by duplex ultrasound* **Dialysis Adequacy**

Zero Vascular Access Recirculation - A New Reality

MacDonald JT Sosa MA, Krivitski NM, Glidden D, Sands JJ, **"Identifying A New Reality: Zero Vascular Access Recirculation Using Ultrasound Dilution,"** ANNA J 1996; 23(6): 603-608. "*A new method, ultrasound dilution, avoids these problems and supports a new clinical reality--zero access recirculation.*"

Alloatti S, Molino A, Bonfant G, Ratibondi S, Bosticardo G M, **"Measurement of Vascular Access Recirculation Unaffected by Cardiopulmonary Recirculation: Evaluation of an Ultrasound Method,"** Nephron 1999; 81(1) 25-30. *"AR determination by USM, avoiding misleading interferences with CPR, is a rapid, easy, and noninvasive method to routinely exclude a potential cause of reduced dialytic efficiency."*

Basile C, Ruggieri G, Vernaglione L, Montanaro A, Giordano R. **"A** comparison of methods for the measurement of hemodialysis access recirculation," J Nephrol. 2003;16(6):908-913. *"AR in autog-*

enous radiocephalic wrist AVFs was zero when measured by means of the USM."

Twardowski ZJ, Van Stone JC, Haynie JD, **"All Currently Used Measurements of Recirculation in Blood Access by Chemical Methods are Flawed Due to Intradialytic Disequilibrium or Recirculation at Low Flow,"** Am J Kid Dis 1998; 32(6): 1046-1058. "*The ultrasound dilution method usually gave lower values than the chemical methods, most likely because of overestimation of recirculation by chemical methods.*"

Lindsay RM, Bradfield E, Rothera C, Kianfar C, Malek P, Blake PG.I, "A Comparison of Methods for the Measurement of Hemodialysis Access Recirculation and Access Blood Flow Rate," ASAIO J 1998; 44: 62-67. "TRANS and HDM appear equal as far as accuracy and repeatability of measurements."

Discrepancy between Prescribed & Delivered HD Pump Flow

Sands J, Glidden D, Jacavage W, Jones B, **"Difference between delivered and prescribed blood flow in hemodialysis,"** ASAIO J. 1996;42(5):M717-M719. "*Delivered and prescribed blood flow (QB) was compared during 208 hemodialysis treatments using the Transonic hemodialysis monitor. Delivered QB averaged 205.6, 300.6, 384.3 (p <* .0001), and 467.7 cc/min (p < .0001) at pump settings of 200, 300, 400, and 500 cc/min."

Depner TA, Rizwan S, Stasi TA, **"Pressure effects on roller pump blood flow during hemodialysis,"** ASAIO Trans. 1990;36(3):M456-M459. "*Blood pump meter readings greater than 400 ml/min were usually inaccurate because of low Pa."*

Kelber J, Delmez JA, Windus DW. "Factors affecting delivery of highefficiency dialysis using temporary vascular access," Am J Kidney Dis. 1993;22(1):24-29. "In spite of the change in arterial line pressure, measured blood flow rate increased appropriately at all set blood flows and with all catheter sites studied."

Teruel JL, Fernández Lucas M, Marcén R, Rodríguez JR, López Sánchez J, Rivera M, Liaño F, Ortuño J, **"Differences between blood flow as indicated by the hemodialysis blood roller pump and blood flow measured by an ultrasonic sensor,"** Nephron. 2000;85(2):142-147.

doi:10.1159/000045647. " The blood flow indicated by the dialysis blood roller pump is always greater than the delivered blood flow, and this difference is in turn conditioned by the negative pressure induced by the blood roller pump in the arterial blood line."

Ward RA, **"Blood Flow Rate: An Important Determinant of Urea Clearance and Delivered Kt/V,"** Adv Ren Replace Ther 2001; 6(1): 75-79. (HD193A) "For quality assurance purposes, actual blood flow rates should be determined by correcting nominal blood flow rates for pressure effects using empirical relationships or by using an ultrasonic flow meter. Because a poorly functioning blood access may further reduce the effective blood flow rate, blood access performance should also be monitored regularly."

Mehta HK, Deabreu D, McDougall JG, Goldstein MB. **"Correction of discrepancy between prescribed and actual blood flow rates in chronic hemodialysis patients with use of larger gauge needles,"** Am J Kidney Dis. 2002;39(6):1231-1235. "*This study shows that the use of larger gauge needles can significantly increase d-BFR and PRU as a result of changes in arterial and venous pressures, resulting in a significantly increased dialysis dose at no additional cost."*

Measurements of Recirculation and Delivered Flow in Catheters

Twardowski ZJ, Haynie JD, **"Measurements of hemodialysis catheter blood flow in vivo,"** Int J Artif Organs. 2002;25(4):276-280. "*Pressures & blood flows were measured at pump speeds from 50 to 500 ml/min in increments of 50 ml/min with lines in normal configuration. Blood flow was measured continuously using ultrasound. The correlations between pressures and flows are not linear."*

Level C, Lasseur C, Chauveau P, Bonarek H, Perrault L, Combe C, "Performance of twin central venous catheters: influence of the inversion of inlet and outlet on recirculation." Blood Purif. 2002;20(2):182-188. "Thus, measurement of the effective blood flow and recirculation by ultrasound velocity should be included in quality monitoring and maintenance."

Leblanc M, Bosc JY, Vaussenat F, Maurice F, Leray-Moragues H, Canaud B, **"Effective Blood Flow and Recirculation Rates in Internal Jugular Vein Twin Catheters: Measurement by Ultrasound Velocity Dilution**," Am J Kid Dis 1998; 31(1): 87-92. *TwinCath delivers an effective Qb of nearly 375 mL/min when Qb is set at 400 mL/min on most dialysis machines. Mean R in TwinCath varies between 5% and 11% for Qb within the range of 200 to 400 mL/min.* Leblanc M, Bosc JY, Paganini EP, Canaud B. **"Central venous dialysis catheter dysfunction,"** Adv Ren Replace Ther. 1997;4(4):377-389. Several recent studies confirm that short femoral catheters recirculate significantly more than is desirable. Well functioning and nonreversed internal jugular and subclavian venous catheters have, in general, recirculation rates less than 5%.

Little MA, Conlon PJ, Walshe JJ, "Access Recirculation in Temporary Hemodialysis Catheters as Measured by the Saline Dilution Technique," Am J Kid Dis 1998; 36(6): 1135-1139. Using ultrasound dilution technology the researchers found "that temporary femoral catheters shorter than 20 cm are associated with increased recirculation rates. ...when dialysis dose delivery is a priority, locating the temporary catheter in the internal jugular vein is an advantage."